Sign in
Acetazolamide for Idiopathic Intracranial Hypertension: An Up-to-Date Review in 2025
Journal article   Open access   Peer reviewed

Acetazolamide for Idiopathic Intracranial Hypertension: An Up-to-Date Review in 2025

Jaffer Naqvi, Michael Wall, Sophia M Chung, Matthew Thurtell, Edward Linton, Adriana Rodriguez-Barrath and Randy Kardon
Eye and brain, Vol.17(1), pp.125-136
2025
DOI: 10.2147/EB.S492845
PMCID: PMC12497366
PMID: 41054617
url
https://doi.org/10.2147/EB.S492845View
Published (Version of record) Open Access

Abstract

Idiopathic Intracranial Hypertension (IIH) is characterized by elevated intracranial pressure in the absence of secondary causes. The treatment of IIH entails a combination of lifestyle modifications, medical therapy, and surgical intervention. This article aims to evaluate the role of acetazolamide in the treatment of IIH and identify its mechanism of action, efficacy, and side effect profile. This article also aims to discuss acetazolamide's role in conjunction with other treatment modalities.
papilledema idiopathic intracranial hypertension acetazolamide

Details

Metrics

Logo image